期刊文献+

N-辛基-O,N-羧甲基壳聚糖自组装纳米粒的制备、理化性质及安全性评价 被引量:2

Preparation,physicochemical properties and safety evaluation of self-assembled nanoparticles based on N-octyl-O,N-carboxymethyl chitosan
下载PDF
导出
摘要 目的:制备两亲性壳聚糖衍生物N-辛基-O,N-羧甲基壳聚糖(OCC)自组装纳米粒,并对其理化性质及安全性进行评价。方法:以透析法制备OCC自组装纳米粒;利用动态光散射(DLS)、Zeta电位仪、透射电镜对其形态、结构进行表征;通过体外溶血实验及小鼠尾静脉注射急性毒性实验评价其安全性。结果:OCC自组装纳米粒粒径为165.6nm,多分散指数为0.191。由于纳米粒表面羧甲基基团的存在,纳米粒表面带负电荷,其表面电势为-30.2mV。透射电镜结果显示该自组装聚合体为规则球形结构,粒径分布均匀。溶血实验和急性毒性实验结果表明,OCC溶血性远远小于Tween 80,与Cremophor EL相当;OCC小鼠尾静脉注射的LD50及95%可信限为560.2(523.0~600.0)mg/kg。结论:OCC自组装纳米粒可初步推断为安全可靠的静脉注射用纳米药物载体。 Aim:To prepare the self-assembled nanoparticles based on carboxymethyl chitosan bearing long alkyl chains (N-octyl-O, N-carboxymethyl chitosan, OCC), characterize the physiochemical properties of OCC self-assembled nanoparticles and meanwhile evaluate the safety profile. Methods: OCC self-assembled nanoparticles were prepared by dia-lysis and characterized using dynamic light scattering, Zeta potential and transmission electron microscopy (TEM). The safety of OCC self-assembled nanoparticles was evaluated by in vitro hemolysis tests and acute toxicity in mice. Results: The mean size of self-assembled nanoparticles was 165.6 nm with polydisperse index of 0. 191 ; The Zeta potential was - 30.2 mV, which were attributed to the carboxymethyl groups on the surface of OCC self-assembled nanoparticles. The TEM images showed a spherical shape. The result of in vitro hemolysis tests showed that OCC self- assembled nanoparticles were safe carriers in terms of the induction of the membrane damage. The LD50 and its 95 % confidence interval of OCC self-assembled nanoparticles in mice were 560.2 (523.0 - 600. 0) mg/kg. Conclusion: The present OCC self-assembled nanoparticles could be potentially useful as safety carriers for the intravenous drug delivery.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2007年第6期512-515,共4页 Journal of China Pharmaceutical University
基金 国家自然科学基金资助项目(No.30472105) 江苏省自然科学基金资助项目(No.BK2007173) 中国药科大学人才引进资金资助项目(No.211073)
关键词 壳聚糖 两亲性 自组装纳米粒 形态 安全性评价 chitosan amphiphilic self-assembled nanoparticles morphology safety evaluation
  • 相关文献

参考文献7

二级参考文献38

共引文献47

同被引文献15

  • 1周建平,霍美蓉.现代药剂学研究新进展[J].中国药科大学学报,2007,38(2):97-104. 被引量:16
  • 2张建军,钱帅,高缘,周建平.喷雾干燥纳米混悬剂提高头孢泊肟酯在大鼠体内的生物利用度[J].中国药科大学学报,2007,38(3):217-220. 被引量:9
  • 3Wong J, Brugger A, Khare A, et al. Suspensions for intravenous (IV) injection : a review of development, preclinical and clinical aspects [ J ]. Adv Drug Deliv Rev,2008,60 (8) :939 - 954.
  • 4Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future[ J]. Adv Drug Deliv Rev,2001,47 (1) :3 -19.
  • 5Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer[ J]. Ann Oncol,2006,17(8) :1 263 - 1 268.
  • 6Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles [ J ] . J Control Release, 2008, doi: 10. 1016/j. jconrel. 2008.05. 010.
  • 7Yi Y, Yoon HJ, Kim BO, et al. A mixed polymeric micellar formulation of itraconazole : Characteristics, toxicity and pharmacokinetics [ J ]. J Control Release,2007,117 ( 1 ) :59 - 67.
  • 8Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosus- pensions. 1. Inhibition of Ostwald ripening [ J ]. Langmuir,2006, 22(3) :906 -910.
  • 9Lindfors L, Forssen S, Skantze P, et al. Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations [ J ]. Langmuir,2006,22 ( 3 ) :911 - 916.
  • 10Lindfors L, Skantze P, Skantze U, et al. Amorphous drug nanosus- pensions. 3. Particle dissolution and crystal growth [ J ]. Langmuir, 2007,23 ( 19 ) : 9 866 - 9 874.

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部